All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
A mutation in the FMS-like tyrosine kinase 3 (FLT3) gene, a recurrent genetic abnormality in acute myeloid leukemia (AML), confers a poor prognostic outcome for patients. Typically, patients with FLT3-mutated AML are treated with intensive chemotherapy, but if patients are ineligible, alternative options are limited.1
Gilteritinib is an oral, small-molecule, second-generation FLT3 inhibitor approved by the U.S. Food and Drug Administration and the European Commission for the treatment of relapsed/refractory AML. The phase III LACEWING (NCT02752035) trial, previously covered by the AML Hub, assessed the efficacy and safety of gilteritinib plus azacitidine versus azacitidine monotherapy in adults with newly diagnosed FLT3-mutated AML. The latest data from this trial were published by Wang, et al., in Blood in 2022, and we are pleased to summarize them below.1
The LACEWING study was a phase III, randomized, open-label trial spanning 185 centers in North America, Europe, and Asia/Pacific. The primary outcome was overall survival (OS), and secondary outcomes included event-free survival (EFS), complete remission (CR) rates, treatment failure and death. Eligible patients were
Figure 1. Eligibility assessment and randomization of patients*
AE, adverse event; AZA, azacitidine; EC, exclusion criteria; GIL, gilteritinib; IC, inclusion criteria.
*Adapted from Wang, et al.1
†Initially, this study included a gilteritinib monotherapy arm (n = 22), but this arm was removed due to changes in the preferred treatment for this patient population.
Enrollment in this study was discontinued for futility based on OS results. As of August 26, 2020, 123 patients were randomized (2:1) to receive either gilteritinib plus azacitidine or azacitidine (Table 1). Nearly three-quarters of patients in each treatment group were aged ≥75 years.
Table 1. Patient characteristics*
Characteristic, % (unless otherwise stated) |
Gil + Aza |
Aza |
---|---|---|
Male |
57 |
57 |
Age, years |
|
|
Median (min–max) |
78 (59–99) |
76 (61–88) |
Baseline ECOG PS |
|
|
0–1 |
51 |
65 |
≥2 |
47 |
33 |
Baseline FLT3 mutation type |
|
|
ITD only |
78 |
82 |
TKD (D835/I836) only |
19 |
14 |
ITD with TKD (D835/I836) |
3 |
4 |
Baseline FLT3 mutation status |
|
|
ITD AR <0.5 |
34 |
37 |
ITD AR ≥0.5 |
47 |
49 |
TKD |
19 |
14 |
Cytogenic risk |
|
|
Favorable |
3 |
0 |
Intermediate |
69 |
74 |
Unfavorable |
11 |
10 |
Other (unknown/missing) |
18 |
16 |
AR, allelic ratio; Aza, azacitidine; BSA, body surface area; ECOG, Eastern Cooperative Oncology Group; FLT3, FMS-like tyrosine kinase 3; Gil, gilteritinib; ITD, internal tandem duplication; PS, performance status; SD, standard deviation; TKD, tyrosine kinase domain. |
Median OS was 9.82 months for the gilteritinib plus azacitidine arm and 8.87 months for the azacitidine only arm (hazard ratio [HR], 0.916 [95% confidence interval [CI], 0.529–1.585]; p = 0.753), with a median follow-up time of 9.76 months and 17.97 months respectively. A survival benefit with gilteritinib plus azacitidine versus azacitidine monotherapy was observed in the following patient subgroups:
However, patients with FLT3-TKD mutations who received gilteritinib plus azacitidine had a shorter OS than those who received azacitidine only (4.86 vs 11.89 months; HR, 2.504 [95% CI, 0.746–8.411]).
Figure 2. Comparison of complete remission rates between treatment groups*
Aza, azacitidine; CR, complete remission; CRc, composite complete remission; CRh, complete remission with incomplete hematological recovery; CRi, complete remission with incomplete platelet recovery; Gil, gilteritinib.
*Adapted from Wang, et al.1
Median EFS was 0.03 months in both treatment arms (HR, 0.925 [95% CI, 0.592–1.444]; p = 0.839). However, sensitivity analysis of EFS based on composite complete remission (CRc) found median EFS was improved in the gilteritinib plus azacitidine group (4.53 months) compared with the azacitidine group (0.03 months).
Adverse event (AE) rates were 100% and 95.7% in the gilteritinib plus azacitidine and azacitidine treatment arms, respectively (Table 2). The AEs leading to death were considered treatment related in four patients in each group. Gastrointestinal hemorrhage and QT prolongation were identified as AEs of special interest, and occurred in 12.3% and 13.7% of patients in the gilteritinib plus azacitidine treatment group, and in 6.4% and 0% of patients in the azacitidine treatment group (Table 2).
Table 2. Adverse events in each treatment group*
Adverse event, % |
GIL+AZA |
AZA |
---|---|---|
Grade ≥3 |
Grade ≥3 |
|
Overall |
95.9 |
89.4 |
Pyrexia |
9.6 |
0 |
Diarrhea |
6.8 |
0 |
Febrile neutropenia |
35.6 |
19.1 |
Anemia |
24.7 |
27.7 |
Thrombocytopenia |
27.4 |
19.1 |
Pneumonia |
20.5 |
17 |
Neutropenia |
21.9 |
21.3 |
Aspartate aminotransferase increased |
5.5 |
0 |
Vomiting |
2.7 |
0 |
Asthenia |
6.8 |
0 |
Hypokalemia |
8.2 |
8.5 |
Decreased appetite |
4.1 |
2.1 |
Neutrophil count decreased |
19.2 |
8.5 |
Platelet count decreased |
17.8 |
19.1 |
Hyponatremia |
12.3 |
2.1 |
Sepsis |
5.5 |
10.6 |
AZA, azacitidine; GIL, gilteritinib. |
There were no substantial differences in gilteritinib trough concentrations at steady state (Ctrough) between gilteritinib plus azacitidine and gilteritinib monotherapy (before removal). Low Ctrough was associated with longer OS and longer median time to discontinuation versus high Ctrough.
Although survival was similar between patients treated with or without gilteritinib alongside azacitidine, in those with high FLT3-ITD allelic burden (allelic ratio ≥0.5), gilteritinib improved OS by 6.3 months. Furthermore, CRc rates were significantly higher in the gilteritinib plus azacitidine arm, although CR rates were similar. The safety profile of gilteritinib in combination with azacitidine was consistent with the profiles of each individual therapy.
Overall, the LACEWING trial demonstrated the safety and favorable clinical activity of gilteritinib plus azacitidine in previously untreated patients with FLT3-mutated AML who are considered unfit for intensive induction chemotherapy. In particular, patients with FLT3-ITD AML and a high allelic burden benefitted most from gilteritinib plus azacitidine, which should be investigated further.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox